Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01)

  • STATUS
    Recruiting
  • End date
    Jan 13, 2025
  • participants needed
    94
  • sponsor
    Sanofi
Updated on 18 November 2022

Summary

Primary Objective:

  • For Cohort A, Cohort B, and Cohort C Part 2: To assess the antitumor activity of tusamitamab ravtansine in metastatic breast cancer (mBC) and tusamitamab ravtansine monotherapy and in combination with gemcitabine in metastatic pancreatic adenocarcinoma (mPAC)
  • For Cohort C Part 1: Confirmation of the recommended tusamitamab ravtansine dose when administered in combination with gemcitabine

Secondary Objectives:

  • To assess the safety and tolerability of tusamitamab ravtansine administered as monotherapy and in combination with gemcitabine
  • To assess other efficacy parameters of tusamitamab ravtansine administered as monotherapy and in combination with gemcitabine
  • To assess the immunogenicity of tusamitamab ravtansine
  • To assess the pharmacokinetics (PK) of tusamitamab ravtansine and gemcitabine when given in combination

Description

The expected duration of study intervention for participants may vary, based on progression date and the cohort; median expected duration of study per participant is estimated at 8 months for Cohort A/C and 6 months for Cohort B (up to 1 month for screening, a median of 4 or 2 months for treatment in Cohort A/C and Cohort B respectively, a median of 1 month for EOT, and follow-up visit 90 days after the last IMP administration).

Details
Condition Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic
Treatment Gemcitabine, SAR408701, Diphenhydramine (pre-medication), tusamitamab ravtansine
Clinical Study IdentifierNCT04659603
SponsorSanofi
Last Modified on18 November 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Participant must be at least 18 years of age
Participants with at least one measurable lesion according to the RECIST v1.1 criteria that has not been irradiated (ie, newly arising lesions in previously irradiated areas are accepted)
Participants with ECOG performance status 0 to 1
Evidence of metastatic disease
Expression of CEACAM 5 by centrally assessed IHC assay
Male and female participants willing to comply with contraceptive use consistent with local regulations regarding the methods of contraception for those participating in clinical studies
Cohort A: mBC
Histological or cytologic diagnosis of breast cancer
Have received at least 2 prior cytotoxic chemotherapy regimens for non-TNBC tumor type or at least 1 for TNBC tumor type but not more than 4 in the locally recurrent or metastatic setting
Have confirmed diagnosis of pancreatic ductal adenocarcinoma
Cohorts B and C: mPAC
Have documented radiographic progression or documented intolerance after at least 1 prior systemic chemotherapy line which included either gemcitabine (or relapsed within 6 months of completion of gemcitabine adjuvant therapy) or a 5-fluorouracil based regimen (including capecitabine) but no more than 2 prior chemotherapy lines for locally advanced/metastatic disease
Cohort B: mPAC
Cohort C: mPAC
Have documented radiographic progression or documented intolerance after 1st line fluoropyrimidine-containing chemotherapy (or relapsed within 6 months of completion of chemotherapy as adjuvant therapy) for locally advanced/metastatic disease

Exclusion Criteria

Medical condition requiring concomitant administration of a medication with a narrow therapeutic window, that is metabolized by cytochrome P450 (CYP450), and for which a dose reduction cannot be considered
Medical conditions requiring concomitant administration of strong CYP3A inhibitor, unless it can be discontinued at least 2 weeks before the first administration of study intervention
Life expectancy less than 3 months
Participants are excluded from the study if any of the following criteria
Untreated brain metastases or history of leptomeningeal disease
apply
Significant concomitant illness
History within the last 3 years of an invasive malignancy other than the one treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment
History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known human immunodeficiency virus (HIV) disease requiring antiretroviral treatment, or active hepatitis A, B or C infection
Non-resolution of any prior treatment-related toxicity to <Grade 2 according to NCI CTCAE v5.0, with the exception of alopecia, vitiligo, or active thyroiditis controlled with hormone replacement therapy (HRT)
Unresolved corneal disorder or any previous corneal disorder considered by an ophthalmologist to predict higher risk of drug-induced keratopathy
Use of contact lenses. Participants using contact lenses who are not willing to stop wearing them for the duration of the study intervention are excluded
Washout period before the first administration of study intervention of less than 3 weeks or less than 5 times the half-life, whichever is shorter, for prior antitumor therapy (chemotherapy, targeted agents, immunotherapy and radiotherapy, or any investigational treatment)
Any prior therapy targeting CEACAM5
Prior maytansinoid DM4 treatment (ADC)
Any major surgery within the preceding 2 weeks of the first study intervention administration
Concurrent treatment with any other anti cancer therapy
Previous enrollment in this study or current participation in any other clinical study involving an investigational study treatment or any other type of medical research
Poor renal function
Poor hepatic function
Poor bone marrow function
potential participation in a clinical trial
Cohort C: mPAC
Any previous systemic therapy with taxane or gemcitabine (for Cohort C only)
The above information is not intended to contain all considerations relevant to the
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note